SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates

SAB Biotherapeutics (NASDAQ:SABS) released its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28), FiscalAI reports.

Here are the key takeaways from SAB Biotherapeutics’ conference call:

• SAFEGUARD enrollment is accelerating, with more than 60 sites actively recruiting and increased screening and randomization. Management remains on track to complete enrollment in Q4 2026, with top-line data expected in the second half of 2027.
• Breakthrough T1D awarded a grant supporting the PRISE-hATG Phase III study, which is expected to begin enrollment in the second half of 2026 across seven sites. If successful, the study could support a future SAB-142 label expansion for patients treated up to two years after diagnosis, with top-line data expected in Q1 2029.
• SAB Bio ended the quarter with $208 million in cash, cash equivalents, and investments, providing an operating runway through 2028. However, higher clinical-development and headcount costs drove R&D expense to $16.2 million and the net loss to $22.5 million, versus $10.1 million a year earlier.
• Management views the recent FDA approval of Tzield in recently diagnosed Stage 3 Type 1 diabetes as validation that C-peptide can support an accelerated-approval pathway. SAB Bio also highlighted SAB-142’s potential competitive advantages, including two-day dosing and low to no immunogenicity that may enable redosing.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS traded up $0.08 during trading hours on Thursday, reaching $3.85. The stock had a trading volume of 279,785 shares, compared to its average volume of 683,940. The stock has a market cap of $294.39 million, a P/E ratio of -1.82 and a beta of 0.53. The stock has a 50 day simple moving average of $3.68 and a 200 day simple moving average of $3.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. SAB Biotherapeutics has a 12-month low of $1.85 and a 12-month high of $5.15.

Institutional Investors Weigh In On SAB Biotherapeutics

Large investors have recently added to or reduced their stakes in the company. State of Wyoming bought a new stake in SAB Biotherapeutics in the 4th quarter valued at about $34,000. State Street Corp bought a new position in SAB Biotherapeutics during the fourth quarter worth about $49,000. ADAR1 Capital Management LLC purchased a new position in shares of SAB Biotherapeutics in the third quarter worth about $30,000. Dimensional Fund Advisors LP purchased a new position in shares of SAB Biotherapeutics in the third quarter worth about $32,000. Finally, Persistent Asset Partners Ltd bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at approximately $74,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Wednesday, July 8th. Barclays started coverage on SAB Biotherapeutics in a research note on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 price objective for the company. Wall Street Zen cut SAB Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday. Leerink Partners boosted their price target on shares of SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, June 15th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $12.00.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.